172 related articles for article (PubMed ID: 23314808)
1. Correlation between erythropoietin receptor(s) and estrogen and progesterone receptor expression in different breast cancer cell lines.
Trošt N; Hevir N; Rižner TL; Debeljak N
Int J Mol Med; 2013 Mar; 31(3):717-25. PubMed ID: 23314808
[TBL] [Abstract][Full Text] [Related]
2. Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells.
Zhang C; Duan X; Xu L; Ye J; Zhao J; Liu Y
Breast Cancer Res Treat; 2012 Dec; 136(3):739-48. PubMed ID: 23117856
[TBL] [Abstract][Full Text] [Related]
3. Recombinant human erythropoietin alters gene expression and stimulates proliferation of MCF-7 breast cancer cells.
Trost N; Stepisnik T; Berne S; Pucer A; Petan T; Komel R; Debeljak N
Radiol Oncol; 2013; 47(4):382-9. PubMed ID: 24294184
[TBL] [Abstract][Full Text] [Related]
4. Erythropoietin receptor expression and correlation to tamoxifen response and prognosis in breast cancer.
Larsson AM; Jirström K; Fredlund E; Nilsson S; Rydén L; Landberg G; Påhlman S
Clin Cancer Res; 2009 Sep; 15(17):5552-9. PubMed ID: 19706814
[TBL] [Abstract][Full Text] [Related]
5. Erythropoietin and its receptor in breast cancer: correlation with steroid receptors and outcome.
Pelekanou V; Kampa M; Kafousi M; Dambaki K; Darivianaki K; Vrekoussis T; Sanidas E; Tsiftsis DD; Stathopoulos EN; Castanas E
Cancer Epidemiol Biomarkers Prev; 2007 Oct; 16(10):2016-23. PubMed ID: 17932349
[TBL] [Abstract][Full Text] [Related]
6. EPO-independent functional EPO receptor in breast cancer enhances estrogen receptor activity and promotes cell proliferation.
Reinbothe S; Larsson AM; Vaapil M; Wigerup C; Sun J; Jögi A; Neumann D; Rönnstrand L; Påhlman S
Biochem Biophys Res Commun; 2014 Feb; 445(1):163-9. PubMed ID: 24502950
[TBL] [Abstract][Full Text] [Related]
7. Lack of G protein-coupled estrogen receptor (GPER) in the plasma membrane is associated with excellent long-term prognosis in breast cancer.
Sjöström M; Hartman L; Grabau D; Fornander T; Malmström P; Nordenskjöld B; Sgroi DC; Skoog L; Stål O; Leeb-Lundberg LM; Fernö M
Breast Cancer Res Treat; 2014 May; 145(1):61-71. PubMed ID: 24715381
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of the erythropoietin receptor in RAMA 37 breast cancer cells alters cell growth and sensitivity to tamoxifen.
Ilkovičová L; Trošt N; Szentpéteriová E; Solár P; Komel R; Debeljak N
Int J Oncol; 2017 Aug; 51(2):737-746. PubMed ID: 28714517
[TBL] [Abstract][Full Text] [Related]
9. Recombinant epoetins do not stimulate tumor growth in erythropoietin receptor-positive breast carcinoma models.
LaMontagne KR; Butler J; Marshall DJ; Tullai J; Gechtman Z; Hall C; Meshaw A; Farrell FX
Mol Cancer Ther; 2006 Feb; 5(2):347-55. PubMed ID: 16505108
[TBL] [Abstract][Full Text] [Related]
10. Inactivation of GPR30 reduces growth of triple-negative breast cancer cells: possible application in targeted therapy.
Girgert R; Emons G; Gründker C
Breast Cancer Res Treat; 2012 Jul; 134(1):199-205. PubMed ID: 22290080
[TBL] [Abstract][Full Text] [Related]
11. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.
Nishimukai A; Yagi T; Yanai A; Miyagawa Y; Enomoto Y; Murase K; Imamura M; Takatsuka Y; Sakita I; Hatada T; Miyoshi Y
Clin Breast Cancer; 2015 Jun; 15(3):204-11. PubMed ID: 25600243
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of erythropoietin expression in human endometrial carcinoma.
Acs G; Xu X; Chu C; Acs P; Verma A
Cancer; 2004 Jun; 100(11):2376-86. PubMed ID: 15160341
[TBL] [Abstract][Full Text] [Related]
13. Tamoxifen through GPER upregulates aromatase expression: a novel mechanism sustaining tamoxifen-resistant breast cancer cell growth.
Catalano S; Giordano C; Panza S; Chemi F; Bonofiglio D; Lanzino M; Rizza P; Romeo F; Fuqua SA; Maggiolini M; Andò S; Barone I
Breast Cancer Res Treat; 2014 Jul; 146(2):273-85. PubMed ID: 24928526
[TBL] [Abstract][Full Text] [Related]
14. Erythropoietin drives breast cancer progression by activation of its receptor EPOR.
Chan KK; Matchett KB; Coulter JA; Yuen HF; McCrudden CM; Zhang SD; Irwin GW; Davidson MA; Rülicke T; Schober S; Hengst L; Jaekel H; Platt-Higgins A; Rudland PS; Mills KI; Maxwell P; El-Tanani M; Lappin TR
Oncotarget; 2017 Jun; 8(24):38251-38263. PubMed ID: 28418910
[TBL] [Abstract][Full Text] [Related]
15. Proteolytic Targeting Chimeras with Specificity for Plasma Membrane and Intracellular Estrogen Receptors.
Lu AS; Rouhimoghadam M; Arnatt CK; Filardo EJ; Salem AK
Mol Pharm; 2021 Mar; 18(3):1455-1469. PubMed ID: 33600191
[TBL] [Abstract][Full Text] [Related]
16. Expression of Hypoxia-Inducible Factor 1α in Invasive Breast Cancer with Metastasis to Lymph Nodes: Correlation with Steroid Receptors, HER2 and EPO-R.
Badowska-Kozakiewicz A; Sobol M; Patera J
Adv Clin Exp Med; 2016; 25(4):741-50. PubMed ID: 27629849
[TBL] [Abstract][Full Text] [Related]
17. GPER mediates the angiocrine actions induced by IGF1 through the HIF-1α/VEGF pathway in the breast tumor microenvironment.
De Francesco EM; Sims AH; Maggiolini M; Sotgia F; Lisanti MP; Clarke RB
Breast Cancer Res; 2017 Dec; 19(1):129. PubMed ID: 29212519
[TBL] [Abstract][Full Text] [Related]
18. miR-125b targets erythropoietin and its receptor and their expression correlates with metastatic potential and ERBB2/HER2 expression.
Ferracin M; Bassi C; Pedriali M; Pagotto S; D'Abundo L; Zagatti B; Corrà F; Musa G; Callegari E; Lupini L; Volpato S; Querzoli P; Negrini M
Mol Cancer; 2013 Oct; 12(1):130. PubMed ID: 24165569
[TBL] [Abstract][Full Text] [Related]
19. No erythropoietin-induced growth is observed in non-small cell lung cancer cells.
Frille A; Leithner K; Olschewski A; Olschewski H; Wohlkönig C; Hrzenjak A
Int J Oncol; 2018 Feb; 52(2):518-526. PubMed ID: 29345289
[TBL] [Abstract][Full Text] [Related]
20. Targeted near-infrared imaging of the erythropoietin receptor in human lung cancer xenografts.
Doleschel D; Mundigl O; Wessner A; Gremse F; Bachmann J; Rodriguez A; Klingmüller U; Jarsch M; Kiessling F; Lederle W
J Nucl Med; 2012 Feb; 53(2):304-11. PubMed ID: 22228796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
